Previous Close | 12.90 |
Open | 12.85 |
Bid | 13.30 x 200 |
Ask | 13.35 x 200 |
Day's Range | 12.85 - 13.60 |
52 Week Range | 12.32 - 32.00 |
Volume | |
Avg. Volume | 418,270 |
Market Cap | 764.072M |
Beta (5Y Monthly) | 0.73 |
PE Ratio (TTM) | 13.82 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.60 (4.65%) |
Ex-Dividend Date | Feb 27, 2024 |
1y Target Est | N/A |
PARSIPPANY, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced its sponsorship of a symposium at the Advanced Technologies & Treatments for Diabetes (ATTD) international conference. This event is scheduled for Wednesday, March 6, at 10:40 a.m. Eastern Standard Time / 14:40 Central European Time. Additionally, six embecta-sponsored abstracts focusing on injection and insulin
PARSIPPANY, N.J., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2023. "Building on our performance during 2023, embecta delivered strong results for the first quarter of 2024," said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta. "During the first quarter, I am pleased to report that we transitioned approximately sixty percent o
PARSIPPANY, N.J., Feb. 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 15, 2024 to stockholders of record at the close of business on February 28, 2024. About embecta embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diab